APRE Key Statistics, Chart & Performance
The current stock price of APRE is 0.9 USD. In the past month the price decreased by -1.87%. In the past year, price decreased by -76.77%.
APRE Technical Analysis
APRE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APRE. APRE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
APRE Financial Highlights
Over the last trailing twelve months APRE reported a non-GAAP Earnings per Share(EPS) of -2.38. The EPS increased by 40.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -91.04% | ||
| ROE | -112.02% | ||
| Debt/Equity | 0 |
APRE Forecast & Estimates
9 analysts have analysed APRE and the average price target is 8.84 USD. This implies a price increase of 882.23% is expected in the next year compared to the current price of 0.9.
For the next year, analysts expect an EPS growth of 28.67% and a revenue growth -78.54% for APRE
APRE Ownership
APRE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.76 | 380.09B | ||
| AMGN | AMGEN INC | 15.15 | 178.40B | ||
| GILD | GILEAD SCIENCES INC | 15.17 | 154.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.52 | 112.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.23 | 76.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 709.06 | 47.77B | ||
| INSM | INSMED INC | N/A | 34.62B | ||
| NTRA | NATERA INC | N/A | 31.98B | ||
| BIIB | BIOGEN INC | 9.85 | 24.20B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.24B | ||
| INCY | INCYTE CORP | 16.63 | 20.96B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.56 | 19.96B |
Related stock screener links
About APRE
Company Profile
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Doylestown, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2019-10-03. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. The company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. The company also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
Company Info
APREA THERAPEUTICS INC
3805 Old Easton Road
Doylestown PENNSYLVANIA 02116 US
CEO: Christian S. Schade
Employees: 8
Phone: 12159484119
APREA THERAPEUTICS INC / APRE FAQ
Can you describe the business of APREA THERAPEUTICS INC?
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Doylestown, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2019-10-03. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. The company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. The company also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
What is the stock price of APREA THERAPEUTICS INC today?
The current stock price of APRE is 0.9 USD. The price increased by 1.12% in the last trading session.
Does APREA THERAPEUTICS INC pay dividends?
APRE does not pay a dividend.
How is the ChartMill rating for APREA THERAPEUTICS INC?
APRE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for APRE stock?
9 analysts have analysed APRE and the average price target is 8.84 USD. This implies a price increase of 882.23% is expected in the next year compared to the current price of 0.9.
What sector and industry does APREA THERAPEUTICS INC belong to?
APREA THERAPEUTICS INC (APRE) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for APREA THERAPEUTICS INC?
APREA THERAPEUTICS INC (APRE) has a market capitalization of 5.68M USD. This makes APRE a Nano Cap stock.